PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK and PD information necessary for clients’ go/no go decisions and to determine appropriate dosing ranges in Phase II studies.
Succeeding with a Risk-Based Approach
A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe…
Early Engagement Crucial to Develop Trial Design for Accelerated Schedule Vaccine Study
A case study describing PRA's involvement in an accelerated schedule vaccine study for poliomyelitis.
The Future of Clinical Trials: Connected and Virtual Approaches for Rare Diseases
Scott Schliebner, Senior Vice President, Center for Rare Diseases at PRA Health Sciences talks about how amore patient-centred approach is needed to…